TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

Scott+Scott, Attorneys at Law, LLP Announces Filing of Securities Class Action Against Teva Pharmaceutical Industries Ltd. (TEVA)

Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, announces that a securities class action has been filed against Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”) (NYSE:TEVA) and certain of its officers and directors. If you purchased Teva American Depository Shares (“ADS”) on the NYSE between November 15, 2016 and August 2, 2017, you are encouraged to contact a Scott+Scott attorney at (844) 818-6982 for more information.

Teva is a pharmaceutical company engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines.

The lawsuit alleges that the defendants misled investors regarding Teva’s business, financial results and operations by, among other things, failing to disclose and actively concealing the negative impact of the Company’s acquisition and integration of Actavis Generics.

On August 3, 2017, Teva announced lower than anticipated second quarter results due to the performance of its U.S. generics business. The Company further recorded a goodwill impairment charge of $6.1 billion in the second quarter of 2017 related to the Company’s acquisition of Actavis. Teva also indicated that its U.S. generics business, due to “accelerated price erosion” and delays in generic launches, was a key factor in lowering Teva’s future guidance and cutting its dividend by 75%.

On this news, the price of Teva ADS dropped from the closing price of $31.25 on August 2, 2017 to a new 52-week-low closing price of $20.60 per ADS on August 4th, a decline of more than one-third. The price has continued to fall and is currently trading before $16 per ADS.

What You Can Do

If you purchased Teva ADS between November 15, 2016 and August 2, 2017 and you wish to discuss this lawsuit, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew at (844) 818-6982, or at [email protected]. The deadline to move for Lead Plaintiff status is October 23, 2017.

About Scott+Scott, Attorneys at Law, LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

EN
30/08/2017

Underlying

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

 PRESS RELEASE

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Applic...

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations1Teva is committed to advancing this innovative treat...

 PRESS RELEASE

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated cli...

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ...

Si Yong Ng
  • Si Yong Ng

Lucror Analytics - Convertibles Brief

In today's Convertibles Brief publication we comment on developments of the following high yield issuers: Teva

Haidje Rustau ... (+5)
  • Haidje Rustau
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng
  • Tanvi Arora

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Virgin Media O2, Italmatch Chemicals, Trivium, Air Baltic, Travelodge, Teva

 PRESS RELEASE

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth ...

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues increased 5% YoY in LC.Key Innovative brands continued to drive growth and provide value for patients, with 2025 revenues surpassing $3 billion, +35% YoY in LC: AUSTEDO® global revenues of $2.26 bill...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch